Last updated: 3 months ago
NeuroSense Therapeutics Ltd. Reports Promising ALS Treatment Findings in Form 6-K
NeuroSense Therapeutics Ltd. unveils key results from its Phase 2b PARADIGM study on PrimeC for ALS, showcasing significant improvements in clinical outcomes and survival rates.